RU2066998C1 - Method of preparing agent used for viral hepatitis a treatment - Google Patents
Method of preparing agent used for viral hepatitis a treatment Download PDFInfo
- Publication number
- RU2066998C1 RU2066998C1 SU925049427A SU5049427A RU2066998C1 RU 2066998 C1 RU2066998 C1 RU 2066998C1 SU 925049427 A SU925049427 A SU 925049427A SU 5049427 A SU5049427 A SU 5049427A RU 2066998 C1 RU2066998 C1 RU 2066998C1
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- ratio
- viral hepatitis
- extraction
- agent used
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 5
- 206010019799 Hepatitis viral Diseases 0.000 title claims description 3
- 201000001862 viral hepatitis Diseases 0.000 title claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000007542 Cichorium intybus Nutrition 0.000 claims abstract description 6
- 241000723343 Cichorium Species 0.000 claims abstract description 5
- 238000000605 extraction Methods 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 241000196324 Embryophyta Species 0.000 claims abstract description 4
- 240000007316 Xerochrysum bracteatum Species 0.000 claims abstract description 3
- 244000025254 Cannabis sativa Species 0.000 claims description 3
- 241000035890 Helichrysum arenarium Species 0.000 claims description 3
- 244000298479 Cichorium intybus Species 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 2
- 241000243812 Arenicola marina Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000608894 Helichrysum Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Изобретение относится к области фармакологии, в частности, к приготовлению лечебных препаратов растительного происхождения. The invention relates to the field of pharmacology, in particular, to the preparation of herbal medicines.
Известен способ получения вещества растительного происхождения для лечения гепатитов и холециститов /1/. A known method of obtaining substances of plant origin for the treatment of hepatitis and cholecystitis / 1 /.
Известный источник не обладает выраженной противовирусной активностью по отношению к эпидемическому гепатиту. A known source does not have a pronounced antiviral activity against epidemic hepatitis.
Цель изобретения повышение активности целевого продукта, сокращение сроков лечения за счет использования в качестве исходного сырья соцветий бессмертника песчаного (Helichrysum arenarium) и травы цикория (Cichorium intubus) в соотношении 1:1. The purpose of the invention is to increase the activity of the target product, reducing the treatment time due to the use of inflorescences of Helichrysum sandworm (Helichrysum arenarium) and chicory grass (Cichorium intubus) in the ratio 1: 1 as a raw material.
Способ осуществляется путем последовательной экстракции суммарного сырья 95%-ным этиловым спиртом и водой в соотношении 1:1 с последующей фильтрацией экстракта и применяемого в качестве целевого препарата названного авторами "Флактуцин". The method is carried out by sequential extraction of the total raw material with 95% ethyl alcohol and water in a ratio of 1: 1, followed by filtration of the extract and used as the target drug called "Flactucin" by the authors.
Пример. Сухое измельченное сырье 100 г соцветий бессмертника песчаного (Helichrysum arenarium) и 100 г травы цикория (Cichorium intybus) помещали в экстрактор, заливали 1000 мл 95%-ного этилового спирта экстрагировали в течение 2 ч при Т +50oС затем вводили в экстрактор 1000 мл дистиллированной воды и дополнительно экстрагировали в течение 2 ч при Т 60oС. Отделяли экстракт от истощенного сырья центрифугой, фильтровали. Получали 1700 мл готового продукта и расфасовывали в плотно-закупоренные банки темного стекла. Флуктуцин применяется перорально.Example. Dry crushed raw materials 100 g of inflorescences of sandy immortelle (Helichrysum arenarium) and 100 g of chicory grass (Cichorium intybus) were placed in the extractor, filled with 1000 ml of 95% ethyl alcohol, extracted for 2 hours at T +50 o C, then introduced into the extractor 1000 ml of distilled water and was additionally extracted for 2 h at T 60 o C. The extract was separated from the depleted feed by centrifuge, filtered. Received 1700 ml of the finished product and packaged in tightly-sealed jars of dark glass. Fluctucin is administered orally.
Препарат проявляет высокую активность при разведении 1:2000 на воде. The drug is highly active when diluted 1: 2000 in water.
Применяется для лечения эпидемического гепатита А (болезнь Боткина). Суточная доза препарата 90 мкл на 60 кг веса (30 мкл с интервалом 6 ч) сроки лечения 3-5 дней. It is used to treat epidemic hepatitis A (Botkin's disease). The daily dose of the drug is 90 μl per 60 kg of weight (30 μl with an interval of 6 hours). The treatment takes 3-5 days.
В результате применения препарата на 21 больном, наблюдались положительные результаты наблюдалось на 21 больном, неопределенных результатов и отрицательных не наблюдалось. As a result of the use of the drug in 21 patients, positive results were observed in 21 patients, uncertain results and negative were not observed.
Возможности современной терапии вирусного гепатита не позволяют ликвидировать патологический процесс. Сроки лечения от 4 недель до нескольких месяцев. Не исключается исход в хронический гепатит (5 8%) и цирроз (3%). The possibilities of modern therapy for viral hepatitis do not allow to eliminate the pathological process. Duration of treatment is from 4 weeks to several months. The outcome in chronic hepatitis (5–8%) and cirrhosis (3%) is not ruled out.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU925049427A RU2066998C1 (en) | 1992-06-25 | 1992-06-25 | Method of preparing agent used for viral hepatitis a treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU925049427A RU2066998C1 (en) | 1992-06-25 | 1992-06-25 | Method of preparing agent used for viral hepatitis a treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2066998C1 true RU2066998C1 (en) | 1996-09-27 |
Family
ID=21607851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU925049427A RU2066998C1 (en) | 1992-06-25 | 1992-06-25 | Method of preparing agent used for viral hepatitis a treatment |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2066998C1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2139722C1 (en) * | 1998-04-13 | 1999-10-20 | Куркин Владимир Александрович | Agent "silibokhol" used for treatment of patients with hepatitis and method of its preparing |
| CN100362995C (en) * | 1997-12-01 | 2008-01-23 | 尼柯根股份有限公司 | CYP2A enzymes and their use in therapeutic and diagnostic method |
-
1992
- 1992-06-25 RU SU925049427A patent/RU2066998C1/en active
Non-Patent Citations (1)
| Title |
|---|
| Машковский М.Д. Лекарственные средства. - М.: Медицина, 1985, т.1, с.516 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100362995C (en) * | 1997-12-01 | 2008-01-23 | 尼柯根股份有限公司 | CYP2A enzymes and their use in therapeutic and diagnostic method |
| RU2139722C1 (en) * | 1998-04-13 | 1999-10-20 | Куркин Владимир Александрович | Agent "silibokhol" used for treatment of patients with hepatitis and method of its preparing |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0175067B1 (en) | Extracts of gingko biloba leaves and their method of preparation | |
| EP0431536B1 (en) | A method of preparation of an extract from Gingko biloba leaves. | |
| Talakal et al. | In vitro and in vivo antitrypanosomal activity of Xanthium strumarium leaves | |
| Sekar et al. | Effect of different fractions of Swertia chirayita on the blood sugar level of albino rats | |
| US5882648A (en) | Methods of disease inhibition using acid polysaccharides extracted from nutshells | |
| WO2012136149A1 (en) | Euphorbia of anti latent hiv and the uses thereof | |
| CN101804127B (en) | A compound traditional Chinese medicine extract composition for preventing and treating senile dementia | |
| EP0216936A1 (en) | Novel tannin composition | |
| RU2066998C1 (en) | Method of preparing agent used for viral hepatitis a treatment | |
| JP2000505065A (en) | Use of drugs and the use of substance mixtures to produce drugs | |
| WO2021191169A1 (en) | 1,2,4-trioxane compounds and compositions comprising the same for use in the treatment of covid-19 | |
| RU2072865C1 (en) | Method of preparing substance showing antiviral and immunostimulating activity | |
| RU2276991C1 (en) | Tonic and actoprotector remedy | |
| RU2046604C1 (en) | Method of preparing agent showing hepatoprotective activity | |
| CN104352531B (en) | Application of the swinging seat nematode grass in hepatic and health products is prepared | |
| JP2729340B2 (en) | Dementia treatment | |
| TW201726159A (en) | Use of a pharmaceutical composition for treating or slowing down an autoimmune-related disease and an active ingredient thereof | |
| CN102727523A (en) | Medicine possessing anti-HIV latent effect and its application | |
| KR100502835B1 (en) | Compositions comprising extract of ganoderma lucidum, oleamide and its structural analogue as an effective component for preventing or treating dementia | |
| CA1194422A (en) | Process for the preparation of a therapeutically useful fraction extracted from mandassi (cyperus articulatus l.) | |
| CN114409544B (en) | Phenylpropanoid with vasodilation activity, and extraction method and application thereof | |
| CN1345728A (en) | Solasodine hydrochlorate and productive method and application in medicine | |
| KR100370501B1 (en) | Composition for treatment of hepatitis b, containing extract of lonicera japonica thunb | |
| KR100558930B1 (en) | Purified extracts obtained from Harpagopitum procumbens and / or Harpagopitum J. heidens, preparation methods thereof and uses thereof | |
| CN120574279A (en) | A triterpenoid saponin compound and its preparation and application |